Table 1.
Immunohistochemical expression of FGF-2, FGFR-2 and FGFR-3 in OSCC and PMOLs.
Fig 1.
Immunohistochemical staining of FGF-2.
(A-D). A, FGF-2 positivity in transformed case of Leukoplakia with dysplasia X 100. B, FGF-2 positivity in transformed cases of OSMF in fibrosis area X 100. C, FGF-2 positivity in epithelium of OSCC X 400. D, FGF-2 positivity in tumor cells OSCC X 400.
Fig 2.
Immunohistochemical staining of FGFR-2 (A-C).
A, FGFR-2 positivity in transformed cases of Leukoplakia with dysplasia X 200. B, FGFR-2 positivity in transformed case of OSMF in fibrosis area X 100. C, FGFR-2 positivity in OSCC X 100.
Fig 3.
Immunohistochemical staining of FGFR-3 (A-C).
A, FGFR-3 positivity in epithelium of Leukoplakia with dysplasia in transformed case X 200. B, FGFR-3 positivity in transformed case of subepithelial fibrosis area of OSMF X 100. C, FGFR-3 positivity in tumor cells of OSCC X 400.
Table 2.
Relation of FGF-2, FGFR-2 and FGFR-3 expression with clinico-pathological parameters in PMOLs.
Table 3.
Association of FGF-2, FGFR-2 and FGFR-3 with clinico-pathological features in OSCC.
Table 4.
Gene expression profile of FGF-2, FGFR-2 & FGFR-3 by Quantitative Real—time PCR.
Fig 4.
Real time PCR results of FGF-2, FGFR-2 and FGFR-3 and frequency of FGF-2, FGFR-2 and FGFR-3 malignant transformation rate (A-D).
Bar diagram showing fold change expression of FGF-2, FGFR-2 and FGFR-3 by Real Time. A, PCR in OSMF, LKP, OSCC and healthy controls. B, Frequency of FGF-2 malignant transformation rate in PMOLs. C, Frequency of FGFR-2 malignant transformation rate in PMOLs. D, Frequency of FGFR-3 malignant transformation rate in PMOLs.
Table 5.
Patients characteristic of malignant transformed and untransformed cases in PMOLS.
Table 6.
Characteristics of the malignant transformed cases.
Table 7.
Logistic regression analysis of variables in PMOLs malignant transformation.